851390-46-0

Usage

Chemical Class

Quinoline derivatives

Nitrogen-containing compound

Yes

Structure

Quinoline ring with amine group at the 4th carbon position, and a methyl group at the 1st carbon position

Potential pharmacological properties

Yes

Use in pharmaceutical research

Studied for potential applications

Synthesis

Can be synthesized through various chemical reactions

Use as a building block

In the synthesis of other organic compounds

Handling precautions

May pose health risks if not handled properly

Upstream product

• 50-00-0 formaldehyd 
• 885951-71-3 tert-butyl (1,2,3,4-tetrahydroquinolin-4-yl)carbamate 
• 1034770-85-8 1-methyl-2,3-dihydroquinolin-4(1H)-one O-methyl oxime 
• 1198-15-8 1-methyl-1,2,3,4-tetrahydroquinolin-4-one 

Relevant academic research and scientific papers

PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDACl and/or HDAC2 activity.

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

2-CYANOPYRROLIDINECARBOXAMIDE COMPOUND

A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is =CH2, =CHF or =CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, 1, 2, 3 or 4.] having the activity inhibiting DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.